A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia by unknown
CASE REPORT Open Access
A novel BCR-ABL1 fusion gene identified by
next-generation sequencing in chronic
myeloid leukemia
Xiaodong Lyu1,2†, Jingke Yang3†, Xianwei Wang2, Jieying Hu2, Bing Liu2, Yu Zhao2, Zhen Guo2, Bingshan Liu1,
Ruihua Fan2 and Yongping Song3*
Abstract
Background: BCR-ABL1 fusion proteins contain constitutively active tyrosine kinases that are potential candidates
for targeted therapy with tyrosine kinase inhibitors such as imatinib in chronic myeloid leukemia (CML). However,
uncharacterized BCR-ABL1 fusion genes can be missed by quantitative RT-PCR (qRT-PCR)-based routine screening
methods, causing adverse effect on drug selection and treatment outcome.
Case presentation: In this study, we demonstrated that the next-generation sequencing (NGS) can be employed
to overcome this obstacle. Through NGS, we identified a novel BCR-ABL1 fusion gene with breakpoints in the BCR
intron 14 and the ABL1 intron 2, respectively, in a rare case of CML. Its mRNA with an e14a3 junction was then
detected using customized RT-PCR followed by Sanger sequencing. Subsequently, the patient received targeted
medicine imatinib initially at 400 mg/day, and later 300 mg/day due to intolerance reactions. With this personalized
treatment, the patient’s condition was significantly improved. Interestingly, this novel fusion gene encodes a fusion
protein containing a compromised SH3 domain, which is usually intact in the majority of CML cases, suggesting
that dysfunctional SH3 domain may be associated with altered drug response and unique clinicopathological
manifestations observed in this patient.
Conclusion: We identified a novel BCR-ABL1 fusion gene using NGS in a rare case of CML while routine laboratory
procedures were challenged, demonstrating the power of NGS as a diagnostic tool for detecting novel genetic
mutations. Moreover, our new finding regarding the novel fusion variant will provide useful insights to improve the
spectrum of the genomic abnormalities recognizable by routine molecular screening.
Keywords: BCR-ABL1, Next-generation sequencing, Chronic myeloid leukemia, SH3 domain, Tyrosine kinase,
Imatinib
Background
Philadelphia translocation, the recurrent genomic re-
arrangement between chromosome 22q11 and 9q34, is a
cytogenetic hallmark of Chronic myeloid leukemia (CML)
[1]. It usually arises between genes BCR and ABL1 in the
intron regions, resulting in the formation of BCR-ABL1
fusion genes and accordingly in the expression of chimeric
gene transcripts with a juxtaposition of e13-a2, e14-a2,
e19-a2, or e1-a2 [1]. These well characterized mRNA
molecules, existed in three principal forms (p210, p190,
and p230), have been screened routinely by multiplex
quantitative RT-PCR (qRT-PCR) assays for diagnostic
purpose in CML patients. However, these screening pro-
cedures have limitations as they were designed for de-
tecting those previously characterized BCR-ABL1 fusion
transcripts [2–14]. A false negative result may occur if a
novel fusion mRNA does not contain sequences
recognizable by primers within commercial or laboratory-
developed screening kits, conferring a negative impact in
treatment selection and therapeutic outcome.
To overcome these challenges, new technologies are in
debt to be developed. The next-generation sequencing
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(NGS) is a powerful tool for detecting genomic abnor-
malities that are both known and previously uncha-
racterized [15, 16]. Due to improved efficiency and
affordability, both whole genome sequencing (WGS) and
whole exome sequencing (WES) in NGS platforms have
become increasingly popular as alternative methods for
detecting unknown and complex pathogenic mutations
in cancer and other diseases [17, 18]. Additionally, tar-
geted NGS applications have also been developed for
known mutations, further facilitating NGS as a diagnos-
tic tool for daily practice [18].
A CML case was presented in the current study. While
both cytogenetic analysis and Fluorescent In-Situ
Hybridization (FISH) suggested a Philadelphia transloca-
tion, Fluorescence one-step multiplex qRT-PCR, a rou-
tinely used screening method, failed to identify any BCR-
ABL1 transcripts. To resolve the discrepancy, we per-
formed genomic sequencing using a WGS in a NGS
platform and identified a novel BCR-ABL1 fusion gene
variant. The related transcript was then detected using
RT-PCR with customized primers followed by Sanger se-
quencing. Our result should provide novel insights in
BCR-ABL1 diagnosis and facilitate the utilization of
NGS as an alternative or daily diagnostic tool in
leukemia.
Methods
Detection of BCR-ABL1 gene rearrangement
Fluorescence one-step RT-PCR was performed as de-
scribed previously [19]. In brief, total RNA was extracted
from bone marrow aspiration samples with RNeasy Kit
(Qiagen, CA, USA) according to vendor’s instruction
and then treated with DNase I (DNA-free; Applied
Biosystems-Ambion, TX, USA) to remove any DNA
contamination. The one-step RT-PCR was then per-
formed using Leukemia Related Fusion Gene Detection
Kit for BCR-ABL p210, p190, or p230 (Yuanqi Bio-
Pharmaceutical, Shanghai, China). For each reaction,
3 μl total RNA was mixed with 20 μl multiplex RT-PCR
Buffer and 2 μl multiplex Enzyme mix in a total volume
of 25 μl. The RT-PCR was conducted at 42 °C for
30 min, 94 °C for 5 min, and followed by 40 cycles 94 °C
for 15 s and 60 °C for 1 min on a 7300 Real Time PCR
System (ABI, USA).
FISH analysis detecting BCR-ABL fusion
We conducted FISH analysis on patient’s bone marrow
aspiration sample using BCR-ABL FISH Probe kit (GP
Medical, Beijing, China) per vender’s instruction. Two
DNA probes targeting the 5′ end of BCR and the 3′ end
of ABL1 were labeled with green and red fluorescent
dye, respectively. In a normal nucleus, the probe-
targeted sequences were located on different chromo-
somes as indicated as separated green and red signals.
However, when fusion occurs in a tumor cell, a yellowish
signal should be observed due to the fusion of BCR and
ABL1 genes, resulting in the colocalization of the green
and red fluorescent signals.
Whole genome sequencing in a next-generation
sequencing platform
Genomic DNA (gDNA) library for next-generation se-
quencing was prepared using TruSeq Nano DNA Library
Preparation Kit (Illumina, San Diego, CA). The gDNAs
were shared into fragments using Covaris and ligated at
both ends with indexed paired-end adaptors (Covaris,
Woburn, MA, USA). The adapter-ligated gDNAS were
purified and then used as templates in a ligation-
mediated PCR for 8 cycles. The PCR amplicons were
quantitated using Qubit 3.0 Fluorometer (Life Technolo-
gies) after removing primers, and then diluted into solu-
tions at 0.75 ng/ul. The magnitude of enrichment were
subsequently estimated using an Agilent 2100 Bioanalyzer
(Agilent Technologies). Paired-end DNA sequencing
was performed on a HiSeq X (Illumina, San Diego, CA).




A 24-year-old male patient presented to the hospital
with significant bilateral cervical lymphadenopathy in
February 2015. Multiple large necrotic lymph nodes was
increased in size from 1 × 1.5 cm to 5 × 3 cm within
10 days. Thoracic computed tomography (CT) detected
additional bilateral axillary lymphadenopathy. The pa-
tient also showed symptoms including constant low
fever, red and swollen gums, and splenomegaly. The pa-
tient was diagnosed as CML upon the completion of
blood and bone marrow examininations. The full blood
count indicated leukocytosis with elevated level of white
blood cells (WBCs, 222 × 109/L), neutrophils (95.3 × 109/L),
platelet (938 × 109/L), and normal level of hemoglobin
(116 g/L). Periphery blood smear analysis suggested gran-
ulocytosis with the presence of circulating myeloblasts
(6 %) and immature granulocytes at various stages
(Table 1). Bone marrow aspiration analysis indicated
hypercellularity with prominent eosinophilia, basophilia,
and elevated level of myeloblasts (5.4 %) and promyelo-
cytes (8 %) (Table 1 and Fig. 1). A decreased level of lym-
phocytes with normal morphology was also observed. The
myeloid/erythroid (M:E) ratio was significantly increased
in both periphery blood and bone marrow (Table 1).
Detection of BACR-ABL1 fusion gene with the NGS
Bone marrow karyotype showed a phenotype of 46,XY,t
(9;22) (q34;q11) [10/10] (Fig. 2). FISH analysis suggested
a possible fusion between the BCR and ABL1 genes.
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However, fluorescent quantitative RT-PCR (qRT-PCR)
failed to detect any previously characterized BCR-ABL1
fusion transcripts p210 (e13-a2 and e14-a2), p190 (e1-
a2), and p230 (e19-a2). To clarify whether a BCR-ABL1
fusion occurred in this patient, we conducted whole gen-
ome sequencing (WGS) analysis on a next-generation
sequencing (NGS) platform. We detected a BCR-ABL1
fusion gene with novel breakpoints in the BCR intron 14
and the ABL1 intron 2, respectively (Fig. 3a). Based on
this finding, we predicted that the fusion junction in the
novel BCR-ABL1 fusion transcript was flanked by se-
quences from the BCR exon 14 (e14) and ABL1 exon 3
(a3), which were used as templates for designing cus-
tomized PCR primers. Through using these primers, we
conducted RT-PCR followed by Sanger sequencing and
identified the corresponding BCR-ABL1 hybrid mRNA
with an e14a3 junction (Fig. 3b). Through NGS, we also
detected nonsynonymous single nucleotide variant
(SNV) in several well-known leukemic genes, including
FLT3 (c.A20G:p.D7G), KIT (c.A1621C:p.M541L), PAX5
(c.C878T:p.T293), and TP53 (c.C215G:p.P72R). How-
ever, it is not clear whether these mutations play any
important roles in leukemogenesis due to either no or
limited reports associated with each of these mutations
in cancer.
Treatment
Diagnosed with CML, the patient was initially treated
with hydroxyurea to improve blood count. Additional
medicines, including antibiotics and anti-infection drugs,
were also prescribed to relief fever, gum swelling and
redness, and other complications. After detecting the
novel BCR-ABL1 fusion gene, imatinib was used at
400 mg/day as a targeted treatment. However, despite an
improved blood count, the patient showed intolerant re-
actions, including raised fever, sore throat, right-side
maxillofacial swelling, etc., after 40 days’ treatment. The
dosage of imatinib was then reduced to 300 mg/day.
The full blood count was significantly improved with a
WBC count at a relatively stable level (3 to 10 × 109/L).
The patient was then released with continued imatinib usage
at 300 mg/day and with periodic follow-up examinations.
Discussion
In this study, we reported that a novel BCR-ABL1 fusion
gene was identified by NGS technology, but not by a
routinely-used, RT-qPCR-based method in a rare case of
CML. Its mRNA transcript was subsequently detected
using RT-qPCR with customized primers. Our result
suggested that the NGS-based application can be
employed as a diagnostic tool in those difficult cases
with novel or complex genomic abnormalities.
CML, a malignant myeloproliferative disorder, originates
from a hematopoietic stem cell that carries a Philadelphia
chromosome, characterized by a reciprocal translocation
between chromosomes 9 and 22, or t (9,22). This trans-
location generates a fusion gene with the juxtaposition of
the BCR gene fragment at the 5′ end and the ABL1 gene
fragment at the 3′end [20]. An in-frame BCR-ABL1 fusion
gene is likely oncogenic, which can be transcribed into
BCR-ABL1 fusion mRNA and translated into BCR-ABL1
fusion protein. As discovered by genomic and cDNA se-
quencing in CML patients, the breakpoint in the ABL1
gene is usually detected in a region between exon 1a and
exon 2 [21]. In rare occasions, the breakpoints were de-
tected in intron region downstream to the exon 2, result-
ing in a smaller fusion gene skipping exon 2 [22]. In the
BCR gene, the breakpoints are most frequently detected in
introns between exons 13 and 14 or exons 14 and 15
within a region recognized as the major breakpoint cluster
region (M-bcr) covering exons 12–16 (e12-e16, or
Fig. 1 Image of bone marrow aspiration (400x) showing hypercellularity
with elevated level of myeloblasts, eosinophils, and basophils
Table 1 Analysis of periphery blood smear and bone marrow
aspiration
Cell type Blood smear Bone marrow aspiration
Cell count (%) Reference
(Mean ± sem)
Cell count (%)
Myeloblast 6.0 0.64 ± 0.33 5.4
Promyelocyte 4.0 1.57 ± 0.60 8.0
Neutrophil
N. myelocyte 11.0 6.49 ± 2.04 18.2
N. metamyelocyte 8.5 7.90 ± 1.97 7.6
N. band 14.5 23.72 ± 3.50 14.6
Neutrophil 14.0 9.44 ± 2.92 13.8
Eosinophil 13.0 0.86 ± 0.61 11.0
Basophil 5.5 0.30 ± 0.05 1.8
Lymphocyte 16.0 22.78 ± 7.04 9.4
Monocyte 7.5 3.00 ± 0.88 4.2
M:E ratio 153:0 3.00 ± 1.00 215:1
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historically known as b1-b5) [1]. The encoding proteins
were termed based on their molecular weight as p210BCR-
ABL1 fusion proteins with junctions described as e13a2 or
e14a2. In rare cases, the breakpoints were found in the
minor bcr (m-bcr) between the two alternative exons e2′
and e2 [23] or μ-bcr between exons 19 and 20 [24–26].
Their encoding proteins were described as p190BCR-ABL1
and p230BCR-ABL1.
In this study, we reported a CML patient with con-
stant low fever, swollen gums, bilaterally cervical lymph-
adenopathy, and splenomegaly. Interestingly, this patient
showed otherwise normal physical and mental condi-
tions. Upon blood and bone marrow tests, this patient
was diagnosed as CML. Further cytogenetic analysis
confirmed the existence of Philadelphia chromosome.
However, routine fluorescent RT-qPCR screening cannot
Fig. 2 Cytogenetic analysis of bone marrow aspiration showing a karyotype 46,xy,t (9;22) (q34;q11). A gene translocation occurred between
chromosomes 9 and 22 resulting Philadelphia chromosomes at the sites as indicated with arrows
Fig. 3 A novel BCR-ABL1 fusion gene and its transcript in a CML case. a Diagram showing the breaking point (or fusion junction) and flanking
sequences from BCR Intron 14 and ABL1 intron 2, which were identified using WGS in a NGS platform. b BCR-ABL1 cDNA sequence around the fusion
junction and related chromatogram are shown. The junction is indicated with an arrow. The origins of cDNA sequences were also indicated
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detect any form of BCR-ABL1 fusion mRNAs that were
previously characterized and detected in the majority of
CML cases. To resolve the discrepancy, we performed
WGS on an Illumina HiSeq X and identified a novel
BCR-ABL1 fusion gene. Although the breakpoint in the
BCR gene is located in intron between exons 13 and 14
within the M-bcr region, the breakpoint in the ABL1 is
novel, located in intron 2, a region downstream to the
exon 2. The resulting fusion gene is presumably tran-
scribed into a smaller fusion mRNA with an e14a3 junc-
tion, skipping the entire exon 2 (174 nucleotides). This
novel transcript was initially undetectable by routine
RT-qPCR-based diagnostic screening as this type of fu-
sion transcripts have only been reported in rare cases
and have not been the subjects for detection using RT-
PCR-based routine BCR-ABL1 screening [22]. This rare
fusion variant was only reported in 4 leukemia cases, in-
cluding one case of CML [27] and three cases of acute
lymphoblastic leukemia (ALL) [28–30], Unlike our
study, none of these studies performed genomic sequen-
cing to show the existence of this fusion gene on the
genomic level. After NGS application, this novel fusion
mRNA (cDNA) was eventually identified using RT-PCR
with a pair of customized primers targeting the BCR
exon 14 (e14) and ABL1 exon 3 (a3), respectively, and
followed by Sanger sequencing of PCR amplicons.
Similar to our study, a recent publication has shown
that an e14a3 transcript was detected by a customized
PCR using primers targeting the BCR exon e13 and the
ABL1 exon a3, but not by the PCR using conventional
primer sets [28]. Thus, if a BCR-ABL1 negative result
was obtained by conventional screening, care should be
taken to avoid misdiagnosis, which may cause an ad-
verse impact on therapeutic outcome. The correct diag-
nosis will allow physicians to make right decisions
whether a targeted therapy (imatinib in this case) or
other treatment plans should be used for better out-
come achievement.
ABL1 protein is a nonreceptor tyrosine kinase contain-
ing a tyrosine kinase domain. The fusion with the BCR
gene creates a fusion protein with an constitutively ac-
tive ABL1 tyrosine kinases, which are believe to be
causative in CML [31]. The majority of BCR-ABL1 pro-
teins contain juxtaposed SH3-SH2 domains, which are
located upstream to the tyrosine kinase domain and
regulate kinase activity through their interactions with
other proteins [32]. It has been shown that the inter-
action between BCR-ABL1 SH3 and RAD51 proline-rich
regions caused RAD51 phosphorylation, resulting in sec-
ondary chromosomal aberrations that contribute to dis-
ease progression and relapse in CML [33]. In contrast,
small protein apoptin, a tumor-selective killer [34], is a
negative regulator of BCR-ABL1 kinase via its ability to
interact with BCR-ABL1 SH3 domain [35]. Moreover, it
has also been suggested that sensitivity to the ABL TKIs
is altered by either SH3-SH2 mutations or the inter-
action between ABL1 SH3-SH2 and other proteins such
as RIN1 [36, 37]. SH3 domain is encoded by ABL1 exons
2 and 3. In our case, the whole exon 2 sequence includ-
ing 51 nucleotides used for encoding the part of the
ABL1 SH3 domain, were excluded in this novel BCR-
ABL1 fusion gene. Thus, this fusion gene is predicted to
encode a fusion protein with a compromised SH3 do-
main. It is not clear whether this SH3 domain truncation
is associated with some of the less common clinical pre-
sentations and drug response including intolerance to
the normal dose of imatinib. Further studies are war-
ranted to clarify these questions.
Through NGS, we also detected nonsynonymous mu-
tations in leukemic genes TP53, FLT3, KIT, and PAX5,
which were co-existed with BCR-ABL1 fusion. This re-
sult suggested that this CML is highly heterogeneous.
TP53, the most frequently mutated gene in cancer, has
often been detected with mutation in acute myeloid
leukemia (AML), ALL, and chronic lymphocytic
leukemia (CLL), predicting poor prognosis [38–40]. Both
FLT3 and KIT mutations have been shown to be associ-
ated with poor prognosis in AML [41, 42], while muta-
tion in the gene PAX5 are considered as signature
mutations in precursor B-ALL [43, 44]. Although all
these genes are frequently mutated in leukemia, the par-
ticular FLT3 and PAX5 mutations identified in this CML
patient have never been reported before in any type of
cancer, while the TP53 and KIT mutations were only de-
scribed in prostate cancer and melanoma [45, 46]. It
should be noted that these novel mutations would be
less likely to be detected by routine PCR-based molecu-
lar screening due to their novelty. Meanwhile, it remains
to be determine whether these mutations are recurrent
and play any pathological role in CML.
Conclusions
Through NGS application, we have identified a novel
BCR-ABL1 fusion (with an e14a3 junction) that is un-
detectable by routine qRT-PCR-based laboratory proce-
dures in a rare case of CML. Due to the correct
diagnosis, the physicians prescribed targeted therapy
using imatinib to this patient, leading to a better treat-
ment outcome. Our NGS result also suggested that this
fusion gene encodes a protein containing a truncated
SH3 domain, which may contribute to the unique clin-
ical presentation and altered drug response in this pa-
tient. Moreover, novel nonsynonymous mutations in the
TP53, FLT3, KIT, and PAX5 genes, are co-existed with
BCR-ABL1 fusion, indicating the high heterogeneity in
this disease. Therefore, this study has demonstrated the
value of NGS as a powerful diagnostic tool for identify-
ing novel and complex genetic mutations.
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